Equities Analysts Set Expectations for BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of BridgeBio Pharma in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($4.50) per share for the year. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($2.56) per share.

Other research analysts also recently issued research reports about the company. Leerink Partners lowered their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. Evercore ISI raised their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Monday, December 23rd. Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a "market perform" rating on the stock. Bank of America boosted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Finally, HC Wainwright restated a "buy" rating and set a $49.00 price objective on shares of BridgeBio Pharma in a report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $48.08.

BridgeBio Pharma Stock Up 1.3 %

BridgeBio Pharma stock traded up $0.50 during trading hours on Thursday, hitting $37.59. The stock had a trading volume of 1,730,131 shares, compared to its average volume of 3,032,252. The business's 50 day simple moving average is $28.53 and its 200-day simple moving average is $26.81. BridgeBio Pharma has a one year low of $21.62 and a one year high of $41.04. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of -15.60 and a beta of 1.05.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its stake in BridgeBio Pharma by 11.7% during the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company's stock worth $122,658,000 after buying an additional 505,481 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of BridgeBio Pharma by 3.5% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,760,457 shares of the company's stock valued at $95,741,000 after acquiring an additional 127,853 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of BridgeBio Pharma by 3.8% in the third quarter. Geode Capital Management LLC now owns 3,413,949 shares of the company's stock valued at $86,936,000 after purchasing an additional 123,540 shares during the period. The Manufacturers Life Insurance Company increased its position in BridgeBio Pharma by 40.5% during the second quarter. The Manufacturers Life Insurance Company now owns 1,534,972 shares of the company's stock worth $38,881,000 after purchasing an additional 442,248 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in BridgeBio Pharma by 8.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,284,802 shares of the company's stock worth $32,711,000 after purchasing an additional 95,605 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 24.66% of the stock is owned by corporate insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.